Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Vertex Pharmaceuticals Inc., ROE, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The data reveals significant fluctuations in net income (loss) and shareholders’ equity over the observed periods, accompanied by varying returns on equity (ROE). These metrics illustrate the company's financial performance and capital efficiency, with some notable patterns and shifts.

Net Income (Loss)
Net income shows a trend of considerable volatility throughout the years. From 2005 to 2011, the company experienced predominantly substantial losses, reaching a peak loss in 2010 with approximately -754.6 million USD. Only in 2011 is a small positive net income of around 29.6 million USD recorded, after which losses resumed in the subsequent years. Starting from 2013, net income continued to be significantly negative, hitting a steep loss in 2014 near -738.6 million USD. A marked turnaround appears from 2016 onwards, with the company achieving positive net income, culminating in a peak of approximately 2.1 billion USD in 2018 and maintaining positive performance through 2023. However, an anomaly arises in 2024 with a sharp loss of -535.6 million USD, contrasting the previous positive trend.
Shareholders’ Equity
Shareholders’ equity demonstrates a general upward trajectory despite fluctuations. Initially, equity grows from 239.2 million USD in 2005 to over 1 billion USD by 2009. There is some variability until about 2013, but a strong and continuous increase is evident starting in 2014, rising from approximately 1.08 billion USD to a high of 17.58 billion USD by 2023. A slight decline to 16.41 billion USD is noted in 2024. This overall increase points to bolstered financial strength and accumulated capital over the long term.
Return on Equity (ROE)
The ROE metric reflects the company’s varying profitability relative to shareholders' equity, initially showing deeply negative returns, which is consistent with the net losses recorded. Its lowest points include values less than -140% in 2007 and 2010. From 2012 to 2016, ROE remains near zero or slightly negative, indicating marginal profitability or breaks even. A definitive improvement is clear from 2017 onwards, where ROE turns positive and peaks at 47.28% in 2018, suggesting highly efficient use of equity capital. Following this peak, ROE stabilizes in the 20-30% range through 2023, before dropping to -3.26% in 2024, mirroring the negative net income in that year.

Overall, the company has transitioned from a period of high losses and negative returns to a phase of substantial profitability and equity growth beginning around 2016. The improved ROE during these later years indicates enhanced capital management and profitable operations. The sudden decline in 2024 warrants further investigation as it interrupts a multi-year trend of financial gains.


Comparison to Competitors

Vertex Pharmaceuticals Inc., ROE, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Vertex Pharmaceuticals Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)